Discussing Side Effects With Patients
The Carlat Psychiatry Report, Volume 14, Number 10, October 2016
Rajnish Mago, MD
Director, Mood Disorders Program, Associate Professor of Psychiatry, Thomas Jefferson University
Dr. Mago discloses that he has received research grants from Alkermes, Allergan (formerly Forest Laboratories), Genomind, and Takeda, and that he has been a paid consultant to Genomind, Guidepoint Global, Otsuka, and Lundbeck. Dr. Carlat has reviewed this article and found no evidence of bias in this educational activity.
As clinicians, we need to fully understand the importance of side effects for our patients. The most important problem in psychopharmacology is that patients stop taking their medication sooner or later. And what is the most frequent single reason for their stopping the medication? Side effects. In this interview, Dr. Rajnish Mago discusses important strategies for discussing side effects with patients.